Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)
Phase of Trial: Phase I/II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs RST 001 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Sponsors Allergan
- 07 Jul 2017 Planned End Date changed from 1 Apr 2017 to 28 Feb 2021.
- 07 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 28 Aug 2019.
- 06 Sep 2016 According to a RetroSense Therapeutics media release, the the low dose cohort of patients had been dosed in August 2016.